Biogen Inc (BIIB) Stock Price Prediction: 2025, 2026, 2030

The post Biogen Inc (BIIB) Stock Price Prediction: 2025, 2026, 2030 by Marc Guberti appeared first on Benzinga. Visit Benzinga to get more great content like this.

Analysts are saying that Biogen could fall by 2030. Bullish on BIIB? Invest in Biogen on SoFi with no commissions. If it’s your first time signing up for SoFi, you’ll receive up to $1,000 in stock when you first fund your account. Plus, get a 1% bonus if you transfer your investments and keep them there until December 31, 2025.

Biogen Inc. (BIIB) has a strong balance sheet and a few fast-growing drugs. U.S. market growth remains strong, but international revenue has been declining. Patent expirations haven’t helped matters, as competitors release generic copycats of some of the company’s top-performing treatments. 

In this article, we’ll look at BIIB’s latest share price, Wall Street sentiment, multiyear price forecasts, and the key factors that are playing a critical role in the company’s path going forward.

Current Stock Overview

Market Cap: $26.71 billion

Trailing P/E Ratio: 16.60

Forward P/E Ratio: 11.65

1-Year Return: 14%

2025 YTD: 19%

BIIB has a consensus Buy rating from 30 analysts, according to Benzinga. The average price target is $188.85 per share. The highest price target is $292, and the lowest is $115. The three most recent ratings suggest a near-term average target of $172. 

Quick Snapshot Table of Predictions & Methodology for Forecasting

Bull & Bear Case

Biogen has multiple high-growth drugs but continues to endure declining international revenue.

Bull Case

• Alzheimer’s drug LEQEMBI, ataxia drug SKYCLARYS, and depression drug ZURZUVAE are key growth drivers that can boost overall sales as they make up larger percentages of total income.
• More than half of Biogen’s revenue comes from the U.S., and that part of the business has continued to grow year over year.  
• A 1.77 quick ratio indicates financial strength and suggests the company can easily cover its current liabilities. 

Bear Case

• International revenue has been decreasing for multiple years, which can drag overall revenue growth rates and make Biogen heavily reliant on U.S. sales growth.
• More than half of product revenue comes from three sources: multiple sclerosis drug TYSABRI, spinal muscular atrophy drug SPINRAZA, and multiple sclerosis drug VUMERITY. 
• Patents have expired on certain legacy products, such as multiple sclerosis drug TECFIDERA, and generic copycats have compressed sales growth. 

Stock Price Prediction for 2026

CoinCodex projects BIIB stock increasing in 2026. LEQEMBI, SKYCLARYS, and ZURZUVAE can drive gains if they continue to gain market share.

Stock Price Prediction for 2027

CoinCodex projects BIIB stock likely decreasing from current levels, but the highest price target implies that the stock may gain value. Declining international revenue and an overreliance on TYSABRI, SPINRAZA and VUMERITY may hurt the stock.

Stock Price Prediction for 2030

CoinCodex projects BIIB stock losing value in 2030. If the company continues to lose international market share, and it can’t adapt quickly enough to expiring patents, shares may decrease in the long run.

Investment Considerations

Biogen has a few drugs that generate most of its sales, but these high-growth products haven’t been enough to reaccelerate international revenue growth. Expiring patents for legacy products like multiple sclerosis drug TECFIDERA can also lead to the stock losing value.

A high quick ratio suggests that the company has a strong balance sheet, however, which gives it flexibility to make additional investments into its pipeline to potentially make up for revenue losses.

The post Biogen Inc (BIIB) Stock Price Prediction: 2025, 2026, 2030 by Marc Guberti appeared first on Benzinga. Visit Benzinga to get more great content like this.